Welcome to our dedicated page for GNCA news (Ticker: GNCA), a resource for investors and traders seeking the latest updates and insights on GNCA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GNCA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GNCA's position in the market.
Genocea Biosciences (Nasdaq: GNCA) announced its Board of Directors voted to wind down operations and terminate remaining employees necessary for an orderly shut down. The company delivered notice to Nasdaq regarding its intention to voluntarily delist from the Nasdaq Capital Market, with a Form 25 filing planned around June 2, 2022. This decision follows a notification from Nasdaq that the company failed to meet compliance with Listing Rule 5450(a)(1) due to its common stock closing bid price being below $1.00 for 30 consecutive days.
Genocea Biosciences (Nasdaq: GNCA) announced plans to explore strategic alternatives to maximize shareholder value, including potential sale or merger options. The company is undertaking a restructuring plan involving a 65% workforce reduction in Q2 2022, alongside a review of its clinical and research programs. Genocea focuses on developing immunotherapies using its proprietary ATLAS platform to target tumor antigens. Currently, it is conducting Phase 1/2a clinical trials for its investigational therapies, GEN-011 and GEN-009.
Genocea Biosciences (NASDAQ: GNCA) reported initial results from the TiTAN clinical trial of GEN-011, a neoantigen-targeted T cell therapy, showing anti-tumor activity in heavily pre-treated patients with advanced solid tumors. While all patients had progressive disease at Day 113, four out of five exhibited stable disease at Day 57, with one patient experiencing a 10% tumor reduction. The PLANET manufacturing process demonstrated a 100% success rate, yielding significant increases in cell dose and potency for upcoming treatments. An investor webcast is scheduled for later today.
Genocea Biosciences (Nasdaq: GNCA) announced an investor webinar coinciding with the AACR Annual Meeting 2022, scheduled for April 8-13. The event will start at 4:30 PM EDT on April 8, featuring a discussion on late-breaking data from the TiTAN™ clinical trial for GEN-011, a neoantigen-targeted T cell therapy. Key speakers include Melissa Johnson, MD, and Genocea's CEO Chip Clark. Attendees can register via Genocea's website, where a webcast replay will also be available. The TiTAN trial evaluates the safety and efficacy of GEN-011 among other parameters.
Genocea Biosciences, Inc. (NASDAQ: GNCA) will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference on March 17, 2022, at 8:40 A.M. ET. Chip Clark, President and CEO, will lead the discussion. A live webcast will be accessible on the investor relations section of Genocea's website, with a replay available for 90 days. Genocea focuses on neoantigen immunotherapies to treat cancer, utilizing its ATLAS™ platform for personalized T cell responses. The company is currently conducting clinical trials for GEN-011 and GEN-009 therapies.
Genocea Biosciences (Nasdaq: GNCA) released its fourth-quarter 2021 update, reporting a cash position of $37.1 million, down from $79.8 million a year earlier. The net loss for Q4 was $13.3 million, slightly improved from $15.0 million in Q4 2020. The company highlighted the ongoing Phase I/2a TiTAN trial for GEN-011, a neoantigen-targeted therapy, and plans to present initial clinical data at the AACR Annual Meeting in April 2022. R&D expenses increased to $10.3 million for Q4 2021, attributed to GEN-011 costs. Genocea also announced a collaboration with Janssen Biotech to explore neoantigens for cancer therapies.
Genocea Biosciences (NASDAQ: GNCA) announces a late-breaking update on the TiTAN trial for GEN-011, a neoantigen-targeted T cell therapy for solid tumors, to be presented at the AACR Annual Meeting 2022. The PLANET manufacturing process generates high-quality T cells, with 100% of patient samples yielding a drug product or in process. Preclinical data suggests that Inhibigens can accelerate tumor growth. TiTAN is a Phase 1/2a study evaluating safety and efficacy, focusing on both dosing regimens.
Genocea Biosciences, Inc. (Nasdaq: GNCA) announced the addition of John Lunger, Chief Patient Supply Officer at Adaptimmune, to its board of directors. This strategic move aims to enhance technical operations and ensure effective delivery of cell therapies. Lunger brings extensive experience in supply chain optimization from his previous roles at Merrimack Pharmaceuticals and Pfizer. Genocea is currently advancing its GEN-011 cell therapy and conducting trials for its GEN-009 vaccine, utilizing its proprietary ATLAS platform to target cancer antigens.
Genocea Biosciences (NASDAQ: GNCA) will host a conference call on March 10 at 8:30 a.m. E.T. to discuss its fourth quarter 2021 financial results and provide a corporate update. Participants can join by calling either (844) 826-0619 for domestic or (315) 625-6883 for international access, using conference ID 1066689. A live webcast will be available on their investor relations page. A replay will be archived for 90 days. Genocea is advancing cancer immunotherapies using its proprietary ATLAS™ platform.
Genocea Biosciences (NASDAQ: GNCA) will present a corporate overview at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 10:40 A.M. ET. CEO Chip Clark will discuss the company’s work in developing next-generation neoantigen immunotherapies, focusing on their proprietary ATLAS™ platform. A live webcast of the presentation will be available on Genocea's investor relations site, with a replay accessible for 90 days.
Genocea aims to create life-changing immunotherapies for cancer by identifying and targeting tumor antigens.
